Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Small Molecule CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. U.S. Small Molecule CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. U.S. Small Molecule CDMO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. U.S. Small Molecule CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Small Molecule CDMO Market Product Movement Analysis
4.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Active Pharmaceutical Ingredients (API)
4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Finished Drug Products
4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD million)
Chapter 5. U.S. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Small Molecule CDMO Market Drug Type Movement Analysis
5.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
5.4. Innovators
5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Generics
5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Small Molecule CDMO Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Small Molecule CDMO Market Application Movement Analysis
6.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Cardiovascular Disease
6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Central Nervous System (CNS) Conditions
6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Autoimmune/Inflammation
6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Small Molecule CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033
7.4. North America
7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. MEA
7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. U.S. Small Molecule CDMO Market Share Analysis, 2024
8.3. Company Profiles
8.3.1. Lonza, Catalent, Inc.
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Thermo Fisher Scientific Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Cambrex Corporation
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Bellen Chemistry
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Siegfried Holding AG
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Recipharm AB
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Eurofins Scientific
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Aurigene Pharmaceutical Services Ltd
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. CordenPharma International
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. Small Molecule CDMO market, by product, 2021 - 2033 (USD Million)
Table 3 U.S. Small Molecule CDMO market, by drug type, 2021 - 2033 (USD Million)
Table 4 U.S. Small Molecule CDMO market, by application, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Small Molecule CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Segment snapshot
Fig. 15 Competitive landscape snapshot
Fig. 16 Parent market outlook, 2024 (USD Million)
Fig. 17 Ancillary market outlook, 2024 (USD Million)
Fig. 18 U S Small Molecule CDMO market dynamics
Fig. 19 Porter’s five forces analysis
Fig. 20 PESTEL analysis
Fig. 21 U S Small Molecule CDMO market Product outlook: Segment dashboard
Fig. 22 U S Small Molecule CDMO market, by Product segment: Market share, 2025 & 2033
Fig. 23 Active Pharmaceutical Ingredients (API) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Finished Drug Products market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 U S Small Molecule CDMO market Drug Type outlook: Segment dashboard
Fig. 26 U S Small Molecule CDMO market, by Drug Type segment: Market share, 2024 & 2033
Fig. 27 Innovators market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 U S Small Molecule CDMO market Application outlook: Segment dashboard
Fig. 30 U S Small Molecule CDMO market, by Application segment: Market share, 2024 & 2033
Fig. 31 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Cardiovascular Disease market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 Central Nervous System (CNS) Conditions market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Autoimmune/Inflammation market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Market participant categorization
Fig. 37 Heat map analysis
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
